[68Ga]ABY-025

N/A

Report date: 2026/05/09 20:00:18
NME

Base Information

Drug Name[68Ga]ABY-025
Drug Alias NameTezatabep matraxetanABY-02568GaABY025[68Ga]-ABY-025ABY-025-[68Ga] +[7] 
ClassificationRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Gallium > 68GaRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionSingle-photon emission-computed tomography enhancersReceptor protein-tyrosine kinase erbB-2 antagonistsPositron-emission tomography enhancers
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsNeoplasm MetastasisStomach NeoplasmsBreast Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSweden
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAffibody Ab
China Registration ClassN/A

Develop Information

Active CompaniesVanderbilt-Ingram Cancer Center
Inactive CompaniesAffibody Ab
Active IndicationsNeoplasm MetastasisStomach NeoplasmsBreast Neoplasms +[5] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A